The relationship between dual antiplatelet treatment (DAPT) score and saphenous venous grafts patency after coronary artery bypass grafting surgery

References

• Kolh P, Windecker S, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46:517–592.
   PubMed Web of Science ®Google Scholar
• Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999;34:1262–1347.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961–972.
   PubMed Web of Science ®Google Scholar
• Parang P, Arora R. Coronary vein graft disease: pathogenesis and prevention. Can J Cardiol. 2009;25:e57–e62.
   PubMed Web of Science ®Google Scholar
• Bourassa MG, Fisher LD, Campeau L, et al. Long-term fate of bypass grafts: the Coronary Artery Surgery Study (CASS) and Montreal Heart Institute experiences. Circulation. 1985;72:V71–8.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, et al., ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–260.
   PubMed Web of Science ®Google Scholar
• Nwasokwa ON. Coronary artery bypass graft disease. Ann Intern Med. 1995;123:528–545.
   PubMed Web of Science ®Google Scholar
• Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic followup of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996;28:616–626.
   PubMed Web of Science ®Google Scholar
• Royse A, Pamment W, Pawanis Z, et al. Patency of conduits in patients who received internal mammary artery, radial artery and saphenous vein grafts. BMC Cardiovasc Disord. 2020;20:148.
   Web of Science ®Google Scholar
• Deb S, Cohen EA, Singh SK, et al. Radial artery and saphenous vein patency more than 5 years after coronary artery bypass surgery: results from RAPS (Radial Artery Patency Study). J Am Coll Cardiol. 2012;60:28–35.
   PubMed Web of Science ®Google Scholar
• Nocerino AG, Achenbach S, Taylor JA. Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting. Am J Cardiol. 2013;112:1576–1579.
   Web of Science ®Google Scholar
• Lopes RD, Hafley GE, Allen KB, et al. Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med. 2009;361:235–244.
   PubMed Web of Science ®Google Scholar
• Oksuz F, Elcik D, Yarlioglues M, et al. The relationship between lymphocyte-to-monocyte ratio and saphenous vein graft patency in patients with coronary artery bypass graft. Biomark Med. 2017;11:867–876.
   Web of Science ®Google Scholar
• Yayla Ç, Canpolat U, Akyel A, et al. Association between platelet to lymphocyte ratio and saphenous vein graft disease. Angiology. 2016; 67:133–138.
   Web of Science ®Google Scholar
• Akyel A, Celik IE, Oksüz F, et al. Red blood cell distribution width in saphenous vein graft disease. Can J Cardiol. 2013;29:448–451.
   PubMed Web of Science ®Google Scholar
• Yarlioglues M, Oksuz F, Yalcinkaya D, et al. CHA2DS2-Vasc score and saphenous vein graft disease in patients with coronary artery bypass graft surgery. Coron Artery Dis. 2020;31:243–247.
   Google Scholar
• Zhao Q, Zhu Y, Xu Z, et al. Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial. JAMA. 2018;319:1677–1686.
   PubMed Web of Science ®Google Scholar
• Verma S, Goodman SG, Mehta SR, Latter DA, et al. Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. BMC Surg. 2015;15:112.
   PubMed Web of Science ®Google Scholar
• Smith PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol. 2012;60:388–396.
   PubMed Web of Science ®Google Scholar
• Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:672–684.
   PubMed Web of Science ®Google Scholar
• Fox KA, Mehta SR, Peters R, et al., Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110:1202–1208.
   PubMed Web of Science ®Google Scholar
• Saw J, Topol EJ, Steinhubl SR, et al., CREDO Investigators. Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. Am J Cardiol. 2004;94:623–625.
   PubMed Web of Science ®Google Scholar
• Gao G, Zheng Z, Pi Y, et al. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol. 2010;56:1639–1643.
   PubMed Web of Science ®Google Scholar
• Sun JC, Teoh KH, Lamy A, et al. Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the preoperative aspirin and postoperative antiplatelets in coronary artery bypass grafting study. Am Heart J. 2010;160:1178–1184.
   PubMed Web of Science ®Google Scholar
• Kulik A, Le May MR, Voisine P, et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the Clopidogrel after Surgery for Coronary Artery Disease (CASCADE) Trial. Circulation. 2010;122:2680–2687.
   PubMed Web of Science ®Google Scholar
• Mannacio VA, Di Tommaso L, Antignan A, et al. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study. Heart. 2012;98:1710–1715.
   PubMed Web of Science ®Google Scholar
• Gasparovic H, Petricevic M, Kopjar T, et al. Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. Am J Cardiol. 2014;113:1660–1667.
   PubMed Web of Science ®Google Scholar
• Long T, Peng L, Li F, et al. Ke Xia, Ran Jing. Correlations of DAPT score and PRECISE-DAPT score with the extent of coronary stenosis in acute coronary syndrome. Medicine. 2018;97:e12531.
   Web of Science ®Google Scholar